private financing

The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.

The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.

The company said it plans to use the funds to build out its annotated immune cell atlas and to expand its functional genomics capabilities.

Four genomics startups will join Illumina's Bay Area program, while five will join the Cambridge, UK program.

The Swedish firm will use the proceeds from the private placement to finance its global marketing and sales expansion.

The firm plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.

The San Diego-based company said it plans to use the funds to speed development of its ProteoCode proteomics platform.

The Seattle-based University of Washington spinout is planning to scale up the commercial roll-out of its single-cell, whole-transcriptome assay kit.